Pharma BD Deal Intelligence
Small bolt-on that paid off: GlycArt's glycoengineering tech underpinned a real (if sub-blockbuster) Roche oncology franchise in Gazyva, still expanding into new indications 20 years later.
Full analysis, sources & comparables →Roche acquires Swiss antibody specialist GlycArt, capturing the GlycoMAb ADCC-enhancement platform and three preclinical oncology mAbs.
Swiss commentators viewed the deal as validation of the ETH Zurich biotech ecosystem and a vote of confidence in Swiss antibody engineering.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Roche acquires Swiss antibody-engineering specialist GlycArt for ~CHF 235M (~$181.6M); GlycoMAb glycosylation platform - basis for obinutuzumab (Gazyva).
Small bolt-on that paid off: GlycArt's glycoengineering tech underpinned a real (if sub-blockbuster) Roche oncology franchise in Gazyva, still expanding into new indications 20 years later.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / GlycArt Biotechnology AG (this deal) | 2005 | $182M | 80 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2005 deals · Roche Holding AG deals